Skip Navigation


ToxSci Advance Access originally published online on April 21, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
80/2/335    most recent
kfh148v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (9)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by He, Q.
Right arrow Articles by Sharma, R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by He, Q.
Right arrow Articles by Sharma, R. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Toxicological Sciences 80, 335-342 (2004)
Toxicological Sciences vol. 80 no. 2 © Society of Toxicology 2004; all rights reserved.

Silymarin Protects Against Liver Damage in BALB/c Mice Exposed to Fumonisin B1 Despite Increasing Accumulation of Free Sphingoid Bases

Quanren He, Jiyoung Kim and Raghubir P. Sharma1

Department of Physiology and Pharmacology, College of Veterinary Medicine, The University of Georgia, Athens, Georgia 30602-7389

Received February 6, 2004; accepted April 7, 2004

Fumonisin B1 (FB1) is a mycotoxin produced by Fusarium verticillioides found on corn and corn-based foods. It causes equine leukoencephalomalacia, porcine pulmonary edema, and liver and kidney damage in most animal species. Fumonisin B1 perturbs sphingolipid metabolism by inhibiting ceramide synthase activity, leading to the production of cell signaling factors including tumor necrosis factor {alpha} (TNF-{alpha}). The signal pathways of TNF-{alpha} are important factors in the pathogenesis of FB1 hepatotoxicity. In the present study, female BALB/c mice were treated daily with 750 mg/kg silymarin by gavage and 2.25 mg/kg FB1 subcutaneously for 3 days. Then, 1 day after the last FB1 injection, the mice were euthanized and blood and tissues were sampled for analyses. Silymarin significantly diminished FB1-induced elevation of plasma alanine aminotransferase and aspartate aminotransferase activities and the number of apoptotic hepatocytes, while it augmented hepatocyte proliferation indicated by an increase in proliferating cells. Silymarin dramatically potentiated FB1-induced accumulation of free sphinganine and sphingosine in both liver and kidney. Silymarin itself slightly increased expression of hepatic TNF-{alpha}; however, it prevented the FB1-induced increases in TNF-{alpha}, TNF receptor 1, TNF receptor–associated apoptosis-inducing ligand, lymphotoxin ß, and interferon {gamma}. The induction of transforming growth factor ß1 expression in liver following FB1 treatment was not affected by silymarin. These findings suggest that silymarin protected against FB1 liver damage by inhibiting biological functions of free sphingoid bases and increasing cellular regeneration.

Key Words: fumonisin B1; silymarin; tumor necrosis factor {alpha}; sphingolipid; hepatotoxicity.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Toxicol SciHome page
Q. He, H. Suzuki, N. Sharma, and R. P. Sharma
Ceramide Synthase Inhibition by Fumonisin B1 Treatment Activates Sphingolipid-Metabolizing Systems in Mouse Liver
Toxicol. Sci., December 1, 2006; 94(2): 388 - 397.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.